Defy Medical’s public TRT cost page describes an average cost spread across a year, while explaining that the practice charges for services when they are purchased. That is different from a fixed monthly subscription.
We reviewed public sources on September 23, 2026. We did not attend a consultation, buy medication or independently measure care quality. CoreAge Rx receives paid featured placement on this publication, including on this page.
Treat the published average as an estimate. Request the actual sequence of assessment, laboratory and prescription charges.
The cost page describes an average
Defy’s FAQ estimates an average TRT cost under $175 per month in the first year and around $125 per month afterward. It says the estimate includes specified medication, laboratory and consultation components, and explicitly warns that individual costs may be higher or lower.
The same page states that Defy does not charge a monthly fee or lock patients into subscriptions or contracts. Charges occur when a service is purchased. A reader therefore needs the initial consultation and testing costs, not just the annual total divided by twelve.
The estimate’s example includes an additional hormone-related medicine. That does not establish that the medicine is necessary for every patient. Ask the clinician to explain each proposed prescription individually. Our cost guide keeps the financial and clinical questions separate.
References: Defy Medical: TRT cost estimate / Endocrine Society: diagnosis and treatment guideline
Map the intake requirements
Defy’s public requirements material describes an initial consultation and follow-up testing and consultation. Its medication-ordering FAQ says medicines such as testosterone require laboratory testing, consultation and a prescription before purchase.
Ask for the current requirements that apply to your location and circumstances, including any physical examination or existing-record requirements. Confirm whether outside results are acceptable and what happens if they are incomplete. We do not treat indexed excerpts from a requirements page as a complete personalized checklist.
The blood-test file explains why diagnosing testosterone deficiency involves more than ordering a commercial panel. A proper evaluation can identify another explanation for symptoms or conclude that treatment is not indicated.
References: Defy Medical: patient requirements / Defy Medical: ordering prescription medicines / Endocrine Society: diagnosis and treatment guideline
Get the product and pharmacy in writing
A clinical practice can offer more than one formulation or pharmacy arrangement. Before comparing medication costs, identify the exact product, route, concentration where relevant, and dispensing pharmacy. Ask whether the preparation is FDA-approved or compounded.
Compounded drugs do not undergo FDA approval. Product-specific evidence and instructions should not be borrowed from another formulation just because both contain testosterone. Use FDA’s online-pharmacy resources to check licensing and ask the pharmacist to explain handling and storage.
We have not verified a particular Defy patient’s pharmacy assignment or dispensed product. The gel-versus-injection comparison provides practical questions, without choosing a formulation or converting doses.
References: FDA: compounding questions and answers / FDA: BeSafeRx pharmacy checks / DailyMed: testosterone gel 1.62% labeling
Separate continuing care from repeat purchasing
Ask how the clinician evaluates symptom changes, treatment response and adverse effects. Agree on who reviews the monitoring results and how decisions are communicated. A pay-as-you-go arrangement needs a clear plan for the timing and cost of that care.
The monitoring file summarizes selected considerations. FDA’s current testosterone update addresses blood-pressure warnings as well as changes to cardiovascular boxed-warning language; it should not be simplified into a risk-free claim.
Tell the clinician about fertility plans before starting. The treatment decision should account for those plans and any need for specialist evaluation, rather than assume a standard package fits everyone.
References: Endocrine Society: diagnosis and treatment guideline / FDA: testosterone labeling changes / Urology Care Foundation: low testosterone
Use the review for a defined comparison
Defy’s public billing explanation is useful when you want to understand an alternative to subscription or minimum-purchase structures. It does not let us predict your annual bill, appointment experience, prescription eligibility or clinical result.
Compare its written estimate with the TRT Nation file, which discusses a different advertised purchase structure. The provider shortlist also marks CoreAge’s paid brand position and unconfirmed TRT availability explicitly.
Before paying, settle the current fees, cancellation terms, service availability and follow-up responsibilities. Put the remaining clinical questions into your appointment brief so a provider comparison leads to a better assessment rather than just another shopping tab.
References: Defy Medical: TRT cost estimate / Defy Medical: patient requirements / TRT Nation: testosterone offer / HHS: licensing across state lines
Source record
- Defy Medical: TRT cost estimate
Illustrative average, not a monthly subscription price or individual guarantee.
- Endocrine Society: diagnosis and treatment guideline
Clinical guidance for men with hypogonadism; not a self-diagnosis tool.
- Defy Medical: patient requirements
Provider intake requirements; indexed official excerpts reviewed if direct access is blocked.
- Defy Medical: ordering prescription medicines
Company statement that prescription medicines require assessment and prescribing.
- FDA: compounding questions and answers
Compounded drugs are not FDA-approved.
- FDA: BeSafeRx pharmacy checks
Official resources for checking online pharmacies.
- DailyMed: testosterone gel 1.62% labeling
Product-specific label. Does not establish safety or equivalence of every compounded formulation.
- FDA: testosterone labeling changes
February 2025 update; cardiovascular boxed-warning language and blood-pressure warnings must be distinguished.
- Urology Care Foundation: low testosterone
Patient education on evaluation, monitoring and fertility. Current FDA update takes precedence for labeling changes.
- TRT Nation: testosterone offer
Provider advertising; listed prices and minimum purchase are not a personal quote or evidence of outcomes.
- HHS: licensing across state lines
Patient location and professional authorization matter for telehealth; not a state-specific legal opinion.
